Drug Profile
Hexyl aminolevulinate - Photocure
Alternative Names: 5-ALA hexylester; 5-ALA hexylesther; aminolevulinic acid hexyl ester; APL-1702; APL-1706; Cevira; Cysview; HAL-PDT; hexaminolevulinate; Hexvix; Hexvix PDT; hexyl 5-aminolevulinate; P 1206Latest Information Update: 24 Apr 2024
Price :
$50
*
At a glance
- Originator PhotoCure
- Developer Asieris Pharmaceuticals; Genotests; Ipsen; Juno Pharmaceuticals; Photocure
- Class Amino acids; Antineoplastics; Esters; Imaging agents; Levulinic acids; Oxidants; Small molecules
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Marketed Bladder cancer
- Preregistration Cervical intraepithelial neoplasia
- Discontinued Colorectal cancer
Most Recent Events
- 17 Apr 2024 Hexyl aminolevulinate - Photocure is available for licensing as of 17 Apr 2024. http://www.asieris.com
- 17 Apr 2024 Asieris Pharmaceuticals expects to be in discussions with the US FDA in second half of 2024 to align with the agency on the registration requirements in the US
- 17 Apr 2024 Asieris Pharmaceuticals intends to submit a pre-NDA communication application to the European Medicines Agency (EMA) in the third quarter of 2024